5 results
2.1 Primary Objective: To evaluate the feasibility of RenalGuard for diuresis-guided fluid replacement therapy (ability to match in and output) (time to desired diuresis>200ml/hour) To evaluate the safety of forced diuresis and fluid…
The objective of the study can be defined into two goals1. Reduction of CIN using the Renalguard with furosemide forced diuresis in patients known with chronic kidney failure whom require an endovascular intervention of the lower limbs. 2. Early…
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…
Primary Objective: To monitor long-term safety of durvalumab (allcohorts)Secondary Objectives: To assess the efficacy of durvalumab in terms of ORR and DOR in patients who undergoretreatment with durvalumab (Cohort 2 only)Secondary ObjectivesTo…
Dose-finding:-To determine the adult equivalent exposure/MTD/recommended Phase II pediatric dose of durvalumab monotherapy and durvalumab in combination with tremelimumab-To determine the safety profile of durvalumab monotherapy, or durvalumab in…